和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02256 和誉-B

未开盘 03-16 16:08:22

12.320

+0.200

+1.65%

最高12.480	最低12.030	成交量144.60万
今开12.120	昨收12.120	日振幅3.71%
总市值82.79亿	流通市值82.79亿	总股本6.72亿
成交额1,776万	换手率0.22%	流通股本6.72亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02256","market":"HK","secType":"STK","nameCN":"和誉-B","latestPrice":12.32,"timestamp":1773648502005,"preClose":12.12,"halted":0,"volume":1446000,"delay":0,"changeRate":0.01650165016501659,"floatShares":672000000,"shares":672000000,"eps":0.10045993477460831,"marketStatus":"未开盘","change":0.2,"latestTime":"03-16 16:08:22","open":12.12,"high":12.48,"low":12.03,"amount":17758020,"amplitude":0.037129,"askPrice":12.39,"askSize":1000,"bidPrice":12.32,"bidSize":41000,"shortable":3,"etf":0,"ttmEps":0.10336552841963496,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773711000000},"marketStatusCode":0,"adr":0,"listingDate":1634054400000,"exchange":"SEHK","adjPreClose":12.12,"openAndCloseTimeList":[[1773624600000,1773633600000],[1773637200000,1773648000000]],"volumeRatio":0.6221935135663561,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02256","defaultTab":"news","newsList":[{"id":"2619481780","title":"和誉-B(02256)：依帕戈替尼联合靶免疗法一线治疗晚期肝细胞癌完成 II期临床首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2619481780","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619481780?lang=zh_cn&edition=full","pubTime":"2026-03-16 08:14","pubTimestamp":1773620062,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，本公司的附属公司上海和誉生物医药科技有限公司宣布，其自主研发的高选择性口服小分子FGFR4抑制剂依帕戈替尼联合标准疗法，已在针对晚期或不可切除肝细胞癌一线治疗的II期临床研究中完成首例患者给药。在2025年欧洲肿瘤内科学会胃肠道肿瘤大会上，和誉医药公布了依帕戈替尼联合阿替利珠单抗治疗HCC的II 期研究结果。除单药治疗之外，和誉医药同时在探索依帕戈替尼联合抗PD-L1抗体的II期试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414064.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和誉-B(02256)：依帕戈替尼联合靶免疗法一线治疗晚期肝细胞癌完成 II期临床首例患者给药","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2778985437.USD","LU2488822045.USD","IE00B5MMRT66.SGD","LU2476274308.USD","LU2476274720.SGD","IE00B543WZ88.USD","BK1161","02256","IE00BPRC5H50.USD"],"gpt_icon":0},{"id":"2618418695","title":"和誉-B盘中异动 早盘大幅下挫5.11%报12.070港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618418695","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618418695?lang=zh_cn&edition=full","pubTime":"2026-03-12 11:05","pubTimestamp":1773284740,"startTime":"0","endTime":"0","summary":"2026年03月12日早盘11时05分，和誉-B股票出现波动，股价大幅跳水5.11%。截至发稿，该股报12.070港元/股，成交量64.3万股，换手率0.10%，振幅5.50%。资金方面，该股资金流入198.867万港元，流出539.469万港元。和誉-B股票所在的生物技术行业中，整体跌幅为2.03%。该公司拥有两款核心候选产品ABSK011和 ABSK091,以及12款其他在研产品。ABSK091 是一种分子靶向候选产品,也是 FGFR亚型 1、2和3的强效和选择性抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312110540a6b995f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312110540a6b995f0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2778985437.USD","IE00BPRC5H50.USD","LU2476274308.USD","LU2488822045.USD","IE00B543WZ88.USD","02256","BK1161","LU2476274720.SGD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2618186911","title":"每日卖空追踪 | 和誉-B 03月11日卖空量成交6.3万股，卖空比例为2.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618186911","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618186911?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:30","pubTimestamp":1773217829,"startTime":"0","endTime":"0","summary":"和誉-B北京时间03月11日，跌0.78%，卖空量成交6.3万股，较上一交易日减少75.49%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163354a460b692&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163354a460b692&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2476274720.SGD","IE00B543WZ88.USD","LU2476274308.USD","02256","IE00BPRC5H50.USD","BK1161","LU2778985437.USD","LU2488822045.USD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2618924186","title":"和誉-B03月11日主力净流出177.5万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2618924186","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618924186?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:16","pubTimestamp":1773216962,"startTime":"0","endTime":"0","summary":"03月11日, 和誉-B股价跌0.78%，报收12.72元，成交金额3285.1万元，换手率0.38%，振幅5.69%，量比1.09。和誉-B今日主力资金净流出177.5万元，上一交易日主力净流入199.8万元。该股近5个交易日上涨16.33%，主力资金累计净流入4.6万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出205.0万元，其中净流出天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311162138a460ac70&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311162138a460ac70&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2778985437.USD","BK1161","02256","LU2476274720.SGD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU2476274308.USD","LU2488822045.USD","IE00BPRC5H50.USD"],"gpt_icon":0},{"id":"2618998304","title":"和誉-B(02256)：FGFR2/3抑制剂ABSK061获FDA授予罕见儿科疾病药物资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2618998304","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618998304?lang=zh_cn&edition=full","pubTime":"2026-03-11 08:14","pubTimestamp":1773188070,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，公司的附属公司上海和誉生物医药科技有限公司宣布，其自主研发的高选择性、口服小分子FGFR2/3抑制剂ABSK061，已获得美国食品药品监督管理局授予用于治疗软骨发育不全的罕见儿科疾病药物资格认定。其口服给药方式在便捷性和治疗依从性方面具有显著优势，尤其对儿科患者而言，这使得ABSK061有望成为治疗儿童和青少年ACH患者的具有潜在价值的治疗候选药物。目前，ABSK061正在开展针对3-12岁儿童ACH患者的II期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412409.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","02256","BK4585","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU2476274720.SGD","LU2778985437.USD","BK1161","IE00BPRC5H50.USD","LU2476274308.USD","LABU","LU2488822045.USD"],"gpt_icon":0},{"id":"2618985985","title":"港股异动 | 和誉-B(02256)再涨超9% 贝捷迈全球III期MANEUVER研究结果荣登《柳叶刀》","url":"https://stock-news.laohu8.com/highlight/detail?id=2618985985","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618985985?lang=zh_cn&edition=full","pubTime":"2026-03-10 13:36","pubTimestamp":1773121010,"startTime":"0","endTime":"0","summary":"和誉-B(02256)再涨超9%，截至发稿，涨8.76%，报12.91港元，成交额2199.69万港元。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260310/20260310133720_71529.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260310/20260310133720_71529.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412041.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02256","BK4585","LU2476274308.USD","VXUS","BK1161","III","IE00B5MMRT66.SGD","LU2476274720.SGD","LU2488822045.USD","IE00B543WZ88.USD","IE00BPRC5H50.USD","BK4588","LU2778985437.USD","BK4134"],"gpt_icon":0},{"id":"1103606349","title":"异动解读 | 利好出尽，和誉-B盘中大跌6.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=1103606349","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103606349?lang=zh_cn&edition=full","pubTime":"2026-03-09 09:37","pubTimestamp":1773020231,"startTime":"0","endTime":"0","summary":"和誉-B(02256)今日盘中股价大幅下挫6.14%，引发市场关注。消息面上，公司近期发布了其核心产品贝捷迈®(盐酸匹米替尼胶囊，ABSK021)全球III期MANEUVER研究的积极结果，该结果已于国际顶级医学期刊《柳叶刀》正式发表，标志着该创新疗法获得了重要的国际学术认可。然而，市场似乎对此利好采取了“卖出事实”的反应。分析认为，尽管该研究数据优异，显示药物在治疗腱鞘巨细胞瘤方面具有显著疗效和良好安全性，且其新药上市申请已获美国FDA受理，但在重大利好消息正式公布后，部分投资者选择获利了结，导致了股价的短期回调。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02256"],"gpt_icon":0},{"id":"2618692617","title":"和誉-B(02256)：《柳叶刀》(The Lancet)发布贝捷迈®全球III期MANEUVER研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2618692617","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618692617?lang=zh_cn&edition=full","pubTime":"2026-03-09 08:03","pubTimestamp":1773014618,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)发布公告，公司的附属公司上海和誉生物医药科技有限公司(和誉医药)宣布，其自主研发的新型、口服、高选择性且高效的小分子CSF-1R抑制剂贝捷迈®(盐酸匹米替尼胶囊，ABSK021)的全球多中心III期MANEUVER研究结果，于3月5日(西欧时间)正式发表于国际医学期刊《柳叶刀》 (The Lancet)1。此次发表标志着和誉医药这一创新疗法在临床研究质量、数据完整性及国际学术认可度方面取得了重要里程碑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411363.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU2476274308.USD","III","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU2488822045.USD","LU2778985437.USD","LU2476274720.SGD","BK4134","IE00BPRC5H50.USD","02256"],"gpt_icon":0},{"id":"1114090662","title":"和誉-B（02256）2026年2月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1114090662","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114090662?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:40","pubTimestamp":1772700043,"startTime":"0","endTime":"0","summary":"和誉开曼有限责任公司于2026年3月5日发布截至2026年2月28日的股份变动月报。公告显示，公司本月无新增发行及注销，股本总体维持稳定。已发行股份及库存股份亦无变化。截至2月底，公司已发行股份总数为672,361,350股，库存股份为7,744,000股，合计680,105,350股，维持与上月相同。在股份期权与激励计划方面，公司2021年9月16日经股东大会批准的首次公开发售后购股权计划共授出9,764,758份期权，报告期内无新增发行或自库存股份转让。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"gpt_icon":0},{"id":"2617543239","title":"每日卖空追踪 | 和誉-B 03月05日卖空量成交7.8万股，卖空比例为3.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617543239","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617543239?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:30","pubTimestamp":1772699429,"startTime":"0","endTime":"0","summary":"和誉-B北京时间03月05日，涨2.9%，卖空量成交7.8万股，较上一交易日减少86.76%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305163345a6a5d8d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305163345a6a5d8d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2778985437.USD","BK1161","02256","LU2476274308.USD","LU2476274720.SGD","LU2488822045.USD","IE00BPRC5H50.USD","IE00B543WZ88.USD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2617459410","title":"和誉-B午前涨逾5% 公司连续第二年实现盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2617459410","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617459410?lang=zh_cn&edition=full","pubTime":"2026-03-05 11:51","pubTimestamp":1772682660,"startTime":"0","endTime":"0","summary":"　　和誉-B盘中涨超6%，截至发稿，股价上涨4.90%，现报11.56港元，成交额1602.54万港元。　　近日，和誉-B发布截至2025年12月31日止年度的年度业绩，该集团取得收入6.12亿元，同比增长21.45%；母公司拥有人应占全面收益2369.8万元，同比减少53.46%；每股基本盈利0.09元。集团连续第二年实现盈利。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-03-05/doc-inhpwzrt9953245.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2476274720.SGD","LU2476274308.USD","LU2488822045.USD","LU2778985437.USD","IE00BPRC5H50.USD","BK1161","02256","IE00B543WZ88.USD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"1151856554","title":"异动解读 | 和誉-B盘中大涨6.08%，受益于连续盈利及核心产品商业化强劲预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1151856554","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151856554?lang=zh_cn&edition=full","pubTime":"2026-03-05 11:21","pubTimestamp":1772680887,"startTime":"0","endTime":"0","summary":"和誉-B今日盘中股价大幅上涨6.08%，引起了市场投资者的关注。消息面上，此次股价波动主要与公司发布的积极年度业绩及核心产品的商业化进展有关。分析指出，在贝捷迈强劲的商业化预期推动下，公司有望步入“创新-变现 - 业绩验证”的新价值循环，为估值持续上行奠定基础，这共同提振了投资者信心，推动了股价在交易时段内的显著上扬。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02256"],"gpt_icon":0},{"id":"2617359904","title":"港股异动 | 和誉-B(02256)涨超6% 公司连续第二年实现盈利 核心产品贝捷迈®商业化预期强劲","url":"https://stock-news.laohu8.com/highlight/detail?id=2617359904","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617359904?lang=zh_cn&edition=full","pubTime":"2026-03-05 11:06","pubTimestamp":1772680006,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和誉-B涨超6%，截至发稿，涨5.63%，报11.64港元，成交额1470.42万港元。消息面上，近日，和誉-B发布截至2025年12月31日止年度的年度业绩，该集团取得收入6.12亿元，同比增长21.45%；母公司拥有人应占全面收益2369.8万元，同比减少53.46%；每股基本盈利0.09元。集团连续第二年实现盈利。截至2025年12月31日止年度，集团已取得收入人民币6.121亿元，利润为人民币5520万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410313.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B5MMRT66.SGD","LU2476274720.SGD","VT","BK4588","VXUS","BK4585","LU2476274308.USD","LU2488822045.USD","IE00B543WZ88.USD","IE00BPRC5H50.USD","BK1161","LU2778985437.USD","02256"],"gpt_icon":0},{"id":"1149722320","title":"异动解读 | 和誉-B盘中大涨5.83%，KRAS抑制剂临床试验获进展及主席增持提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1149722320","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149722320?lang=zh_cn&edition=full","pubTime":"2026-03-04 09:41","pubTimestamp":1772588478,"startTime":"0","endTime":"0","summary":"和誉-B今日盘中股价大幅上涨5.83%，引起了市场的广泛关注。ABSK141是一种针对KRAS G12D突变的高选择性抑制剂，该突变常见于胰腺癌、结直肠癌等多种实体瘤中，目前尚无获批的靶向疗法，因此其临床进展备受关注。同时，徐耀昌博士的增持行为进一步巩固了其持股比例，显示了管理层对公司价值的认可。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02256"],"gpt_icon":0},{"id":"2616303518","title":"和誉-B(02256)：和誉医药口服小分子KRAS G12D抑制剂 ABSK141完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2616303518","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616303518?lang=zh_cn&edition=full","pubTime":"2026-03-04 08:03","pubTimestamp":1772582585,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)发布公告，公司的附属公司上海和誉生物医药科技有限公司宣布，其口服、高效、高选择性小分子KRAS G12D抑制剂ABSK141，已在针对携带KRAS G12D突变的晚期实体瘤患者的I/II期临床试验中已成功完成首例患者给药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409730.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2476274308.USD","02256","IE00B5MMRT66.SGD","LU2488822045.USD","159938","BK1574","09939","BK1161","IE00B543WZ88.USD","IE00BPRC5H50.USD","LU2476274720.SGD","BK1515","LU2778985437.USD"],"gpt_icon":0},{"id":"2616406203","title":"和誉-B(02256)获创始人、执行董事、首席执行官兼董事会主席徐耀昌增持公司4.5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2616406203","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616406203?lang=zh_cn&edition=full","pubTime":"2026-03-03 20:37","pubTimestamp":1772541424,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)发布公告，公司董事会获本公司创始人、执行董事、首席执行官兼董事会主席徐耀昌博士(徐博士)告知，其已于2026年3月3日于公开市场购买合计4.5万股本公司普通股(股份)，平均价格为每股股份约港币11.26元，占本公司全部已发行股份总数约0.01%。紧随购买后，徐博士于合共81,769,968股股份中拥有权益，占于本公告日期本公司全部已发行股份总数约12.02%。据徐博士告知，其对本集团的业务前景及增长充满信心。在符合适用的法律及监管要求下，徐博士不排除会在适当时候进一步增持本公司股份的可能性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409636.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2778985437.USD","IE00BPRC5H50.USD","LU2476274308.USD","LU2488822045.USD","IE00B543WZ88.USD","02256","BK1161","LU2476274720.SGD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"1109017023","title":"和誉-B首席执行官于公开市场增持4.5万股，每股均价11.26港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1109017023","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109017023?lang=zh_cn&edition=full","pubTime":"2026-03-03 20:36","pubTimestamp":1772541386,"startTime":"0","endTime":"0","summary":"3月3日，和誉-B（股票代码：02256）首席执行官在公开市场进行了股份增持操作，总计购入公司股份45,000股。此次交易的平均价格为每股11.26港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","LU2476274720.SGD","LU2488822045.USD","BK1161","02256","LU2778985437.USD","IE00B5MMRT66.SGD","LU2476274308.USD","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"1154569389","title":"异动解读 | 和誉-B盘中大跌5.56%，业绩全面收益下滑及高管变动引发市场担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1154569389","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154569389?lang=zh_cn&edition=full","pubTime":"2026-03-03 09:48","pubTimestamp":1772502486,"startTime":"0","endTime":"0","summary":"和誉-B今日盘中股价大幅下挫5.56%，引起了投资者的广泛关注。消息面上，公司于前一日盘后发布了截至2025年12月31日止年度的年度业绩。尽管报告期内公司收入同比增长21.45%至6.12亿元人民币，且净利润同比大幅增长约95%，但母公司拥有人应占全面收益仅为2369.8万元人民币，同比大幅减少53.46%。市场分析认为，全面收益的显著下滑、缺乏股息派发以及关键管理职位的变动，共同构成了今日股价承压的主要原因。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02256"],"gpt_icon":0},{"id":"2616932360","title":"和誉-B(02256)：年报释放持续规模盈利信号，商业化元年开启全新增长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2616932360","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616932360?lang=zh_cn&edition=full","pubTime":"2026-03-03 07:56","pubTimestamp":1772495814,"startTime":"0","endTime":"0","summary":"净利润同比大增近100%，连续第二年实现年度盈利，在创新研发和BD交易的加持下，2025年的和誉-B再次用亮眼的年度业绩，验证了持续规模盈利的预期，向市场进一步传递了积极的配置信号。据智通财经APP了解，近日，和誉的2025年年度业绩新鲜出炉。随着贝捷迈研发与商业化进程的持续推进，2025年4月1日，默克再次宣布行使全球商业化选择权，支付8500万美元锁定匹米替尼全球权益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409235.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU2476274308.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU2488822045.USD","LU2778985437.USD","LU2476274720.SGD","IE00BPRC5H50.USD","02256"],"gpt_icon":0},{"id":"2616355357","title":"和誉-B(02256.HK)2025年度利润为5520万元 同比增长约95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616355357","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616355357?lang=zh_cn&edition=full","pubTime":"2026-03-02 22:27","pubTimestamp":1772461624,"startTime":"0","endTime":"0","summary":"格隆汇3月2日丨和誉-B(02256.HK)发布截至2025年12月31日止年度的年度业绩。截至2025年12月31日止年度，集团已录得收入人民币6.12亿元(为收取的默克授权收入)，利润为人民币5520万元，同比增长约95%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260302/32038813.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU2488822045.USD","IE00BPRC5H50.USD","LU2476274720.SGD","BK1161","LU2778985437.USD","LU2476274308.USD","02256","IE00B5MMRT66.SGD","IE00B543WZ88.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abbisko.com","stockEarnings":[{"period":"1week","weight":0.0379},{"period":"1month","weight":-0.0412},{"period":"3month","weight":-0.0901},{"period":"6month","weight":-0.268},{"period":"1year","weight":0.5556},{"period":"ytd","weight":-0.053}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":-0.0276},{"period":"3month","weight":0.0237},{"period":"6month","weight":-0.0399},{"period":"1year","weight":0.0782},{"period":"ytd","weight":0.0079}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和誉开曼有限责任公司是一家临床阶段生物制药公司。该公司致力于发现和开发创新差异化的小分子肿瘤疗法。该公司拥有两款核心候选产品ABSK011和 ABSK091，以及12款其他在研产品。ABSK011是一种强效且高选择性的成纤维细胞生长因子受体4(FGFR4) 小分子抑制剂。ABSK091 是一种分子靶向候选产品，也是 FGFR亚型 1、2和3的强效和选择性抑制剂。该公司的产品主要用于肝细胞癌(HCC)、尿路上皮癌(UC) 和胃癌(GC)。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.122249},{"month":2,"riseRate":0.8,"avgChangeRate":0.040621},{"month":3,"riseRate":0.4,"avgChangeRate":0.037396},{"month":4,"riseRate":0.25,"avgChangeRate":-0.010041},{"month":5,"riseRate":0.25,"avgChangeRate":0.029375},{"month":6,"riseRate":0.5,"avgChangeRate":0.006841},{"month":7,"riseRate":0.75,"avgChangeRate":0.047273},{"month":8,"riseRate":0.5,"avgChangeRate":0.114048},{"month":9,"riseRate":0.75,"avgChangeRate":0.043844},{"month":10,"riseRate":0.5,"avgChangeRate":-0.043137},{"month":11,"riseRate":0.6,"avgChangeRate":0.159978},{"month":12,"riseRate":0,"avgChangeRate":-0.092694}],"exchange":"SEHK","name":"和誉-B","nameEN":"ABBISKO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和誉-B(02256)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和誉-B,02256,和誉-B股票,和誉-B股票老虎,和誉-B股票老虎国际,和誉-B行情,和誉-B股票行情,和誉-B股价,和誉-B股市,和誉-B股票价格,和誉-B股票交易,和誉-B股票购买,和誉-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和誉-B(02256)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}